A 30-year-old woman developed a slowly progressive reddish-violet multinodular rubbery lesion, measuring 20 x 10 cm in diameter, on the upper outer quadrant of her right breast four years after the surgical excision of a dermatofibrosarcoma protuberans (DFSP) in the same area. The diagnosis of DFSP was confirmed histologically and by positive immunomarkers at immunohistochemistry. A complete excision was performed and after a 2-year follow-up no recurrence was observed. It should be emphasized that DFSP of the breast is a rare occurrence.
Context: The phenotypic variability of patients with syndromes presenting with dysmorphism makes clinical diagnosis difficult, leading to an exhaustive genetic study to determine the underlying mechanism so that a proper diagnosis could be established. Objective: To genetically characterize siblings, the older sister diagnosed with Albright hereditary osteodystrophy and the younger one with CHARGE syndrome. Design: Clinical case report. Methods: Clinical, biochemical, and radiological studies were performed on the family. In addition, molecular genetic studies including sequencing of GNAS, typing of microsatellites on 2q and 21q, and multiplex ligation-dependent probe amplification of subtelomeric regions were performed, as well as confirmatory fluorescent in situ hybridization analysis. Results: The genetic analysis revealed that both sisters presented a 2q37 deletion due to the maternal unbalanced segregation of a 2;21 translocation. Conclusions: This is the first report of a 2q37 deletion where differential diagnosis of CHARGE syndrome is needed due to the appearance of choanal atresia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.